March 30, 2021
Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appoin
Read MoreMarch 23, 2021
Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that it has entered a co-development agreement with InterVivo Solutions Inc. ("InterVivo" or "IVS"), to co-develop a new tran
Read MoreMarch 22, 2021
TORONTO, March 22, 2021 /CNW/ - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp., as sole bookrunner and lead underwriter (the "Lead Underwriter") pursuant to which the Lead Underwriter has agreed, on behalf of a syndicate of underwriters (together with the Lead Underwrit
Read MoreMarch 22, 2021
TORONTO, March 22, 2021 /CNW/ - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that in connection with its previously announced bought deal public offering, the Company and Canaccord Genuity Corp., as sole bookrunner and lead underwriter (the "Lead Underwriter"), on behalf of a syndicate of underwriters (together with the Lead Underwri
Read MoreMarch 17, 2021
Toronto, Ontario--(Newsfile Corp. - March 17, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has received confirmation of eligibility from The Depository Trust Company ("DTC") for elect
Read MoreMarch 15, 2021
Toronto, Ontario--(Newsfile Corp. - March 15, 2021) - Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has filed a sixth provisional patent application with the United States Patent and Trademark Office. This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine ("DMT") and 5-methoxy-N,N-dimethyltryptamine
Read MoreMarch 8, 2021
Toronto, Ontario--(Newsfile Corp. - March 8, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company") is pleased to announce that it has appointed Dr. Joseph Gabriele, a molecular pharmacologist specializing in signal transduction within the central nervous system, to its scientific advisory board ("Scientific Advisory Board"). Dr. Gabriele specializes in molecular pharmacol
Read MoreFebruary 22, 2021
Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has engaged a leading international contract development and manufacturing organization ("CDMO") to synt
Read MoreFebruary 19, 2021
Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-bas
Read MoreFebruary 10, 2021
Toronto, Ontario--(Newsfile Corp. - February 10, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that several of its proprietary, novel and diverse psychedelic compounds are demonstrating strong potency and e
Read MoreFebruary 5, 2021
Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce that the Company has filed 3 final patent applications with the U.S. Patent and Trademark Offi
Read MoreFebruary 1, 2021
Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has selected a subset of representative compounds belonging to its proprietary third family of patent-pe
Read MoreJanuary 27, 2021
Toronto, Ontario--(Newsfile Corp. - January 27, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that its common shares have been accepted for listing on the Frankfurt Stock Exchange (the "FSE") and commenced t
Read MoreJanuary 20, 2021
Toronto, Ontario--(Newsfile Corp. - January 20, 2021) - Mindset Pharma Inc. (CSE:MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has been invited to present at the inaugural KCSA Psychedelic Investor Conference being held on Tuesday, January 26, 2021
Read MoreJanuary 14, 2021
Toronto, Ontario--(Newsfile Corp. - January 14, 2021) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce it has been invited to present at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being he
Read MoreJanuary 6, 2021
Toronto, Ontario--(Newsfile Corp. - January 6, 2021) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third fam
Read MoreDecember 31, 2020
Toronto, Ontario--(Newsfile Corp. - December 31, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that the Company has entered into an arm's-len
Read MoreDecember 29, 2020
Toronto, Ontario--(Newsfile Corp. - December 29, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has filed another provisional patent ap
Read MoreDecember 22, 2020
Toronto, Ontario--(Newsfile Corp. - December 22, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that the common shares of the Company will commence trading on the Canad
Read MoreDecember 16, 2020
Toronto, Ontario--(Newsfile Corp. - December 16, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has closed an additional non-brokered private placement, pursuant to which t
Read MoreDecember 15, 2020
Toronto, Ontario--(Newsfile Corp. - December 15, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has upsized and completed its previously announced brokered private placemen
Read MoreNovember 9, 2020
Toronto, Ontario--(Newsfile Corp. - November 9, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has entered into a secured convertible promissory note transaction with the
Read MoreOctober 20, 2020
Toronto, Ontario--(Newsfile Corp. - October 20, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company at the forefront of the evolving psychedelics space, today announced that it has begun confirmatory in-vivo studies with InterVivo Solutions Inc. ("InterVivo Solutions") to further profile the efficacy, safety and pharmacological properties of Mindset's
Read MoreSeptember 15, 2020
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2020) - Mindset Pharma Inc. (formerly, North Sur Resources Inc.) (the "Company") is pleased to announce that it has completed its previously announced business combination with Mindset Pharma Inc. ("Mindset"). The business combination was carried out pursuant to the terms of a share exchange agreement (the "Share Exchange Agreement") da
Read MoreAugust 31, 2020
TORONTO, Aug. 31, 2020 -- Mindset Pharma ("Mindset"), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric indications with unmet needs, announces today the preliminary screening results of certain patent-pending compounds.
Read More